Matias Iglicki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8262136/publications.pdf

Version: 2024-02-01

713332 567144 22 879 15 21 citations h-index g-index papers 22 22 22 790 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMOâ€"Is there any difference? the VITDEX study. Eye, 2023, 37, 280-284.	1.1	12
2	Central serous chorioretinopathy imaging biomarkers. British Journal of Ophthalmology, 2022, 106, 553-558.	2.1	23
3	Next-generation anti-VEGF agents for diabetic macular oedema. Eye, 2022, 36, 273-277.	1.1	30
4	Occlusive retinal vasculopathy with macular branch retinal artery occlusion as a leading sign of atypical hemolytic uremic syndrome – a case report. BMC Ophthalmology, 2021, 21, 65.	0.6	7
5	Longer-acting treatments for neovascular age-related macular degenerationâ€"present and future. Eye, 2021, 35, 1111-1116.	1.1	17
6	Detection of Diabetic Retinopathy from Ultra-Widefield Scanning Laser Ophthalmoscope Images: A Multicenter Deep Learning Analysis. Ophthalmology Retina, 2021, 5, 1097-1106.	1.2	36
7	Outer retinal hyperreflective deposits (ORYD): a new OCT feature in naĀve diabetic macular oedema after PPV with ILM peeling. British Journal of Ophthalmology, 2020, 104, 666-671.	2.1	27
8	Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmologica, 2020, 98, e217-e223.	0.6	75
9	Subclinical subretinal fluid detectable only by optical coherence tomography in choroidal naevi—the SON study. Eye, 2020, 35, 2038-2044.	1.1	1
10	Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity. Acta Ophthalmologica, 2020, 98, e801-e806.	0.6	11
11	One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation. British Journal of Ophthalmology, 2020, 104, 678-683.	2.1	7
12	Results in comparison between 30 gauge ultrathin wall and 27 gauge needle in sutureless intraocular lens flanged technique in diabetic patients: 24-month follow-up study. Acta Diabetologica, 2020, 57, 1151-1157.	1.2	17
13	Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant. British Journal of Ophthalmology, 2019, 103, 463-468.	2.1	8
14	TRActional Diabetic reTinal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY. Acta Diabetologica, 2019, 56, 1141-1147.	1.2	42
15	The Role of Steroids in the Management of Diabetic Macular Edema. Ophthalmic Research, 2019, 62, 231-236.	1.0	86
16	Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the †DR-Pro-DEX Study'. Acta Diabetologica, 2018, 55, 541-547.	1.2	74
17	Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetologica, 2018, 55, 789-796.	1.2	91
18	CHANGES IN CHOROIDAL THICKNESS IN CLINICALLY SIGNIFICANT PSEUDOPHAKIC CYSTOID MACULAR EDEMA. Retina, 2018, 38, 1629-1635.	1.0	16

#	Article	IF	CITATIONS
19	OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology, 2018, 125, 267-275.	2.5	188
20	Disorganization of Retinal Inner Layers as a Biomarker for Idiopathic Epiretinal Membrane After Macular Surgeryâ€"The DREAM Study. American Journal of Ophthalmology, 2018, 196, 129-135.	1.7	66
21	Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naÃve diabetic macular edema: The VITAL Study. PLoS ONE, 2018, 13, e0200365.	1.1	45
22	Reply. Ophthalmology, 2018, 125, e61-e62.	2.5	O